ArticleInfection and immunity2011
In vivo regulation of the Vi antigen in Salmonella and induction of immune responses with an in vivo-inducible promoter.
Article in Infection and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Multivalent vaccines for invasiveInfection and immunity · 2026Review
- Article
- Article
- Antibodies and Protection in SystemicInfection and immunity · 2020Review
- Latex proteins downregulate inflammation and restores blood-coagulation homeostasis in acute Salmonella infection.Memorias do Instituto Oswaldo Cruz · 2020Article
- Virulotyping of Salmonella enterica serovar Typhi isolates from Pakistan: Absence of complete SPI-10 in Vi negative isolates.PLoS neglected tropical diseases · 2018Article
- Functional analysis of Salmonella Typhi adaptation to survival in water.Environmental microbiology · 2018Article
- Reciprocal Regulation of OmpR and Hfq and Their Regulatory Actions on the Vi Polysaccharide Capsular Antigen in Salmonella enterica Serovar Typhi.Current microbiology · 2018Article
- Bi-valent polysaccharides of Vi capsular and O9 O-antigen in attenuatedNPJ vaccines · 2018Article
- Salmonella enterica Serovar Typhi Lipopolysaccharide O-Antigen Modification Impact on Serum Resistance and Antibody Recognition.Infection and immunity · 2017Article
- Vi Capsular Polysaccharide Produced by RecombinantFrontiers in cellular and infection microbiology · 2017Article
- Salmonella Extracellular Matrix Components Influence Biofilm Formation and Gallbladder Colonization.Infection and immunity · 2016Article
- Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.PloS one · 2016Article
- Now you see me, now you don't: the interaction of Salmonella with innate immune receptors.Nature reviews. Microbiology · 2015Review
- Salmonella as a vaccine delivery vehicle.Expert review of vaccines · 2013Review
- The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- High-resolution genotyping of the endemic Salmonella Typhi population during a Vi (typhoid) vaccination trial in Kolkata.PLoS neglected tropical diseases · 2012Article
- A Salmonella Typhimurium-Typhi genomic chimera: a model to study Vi polysaccharide capsule function in vivo.PLoS pathogens · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Salmonella enterica serovar Typhi, the agent of typhoid fever in humans, expresses the surface Vi polysaccharide antigen that contributes to virulence. However, Vi expression can also be detrimental to some key steps of S. Typhi infectivity, for example, invasion, and Vi is the target of protective immune responses. We used a strain of S. Typhimurium carrying the whole Salmonella pathogenicity island 7 (SPI-7) to monitor in vivo Vi expression within phagocytic cells of mice at different times after systemic infection. We also tested whether it is possible to modulate Vi expression via the use of in vivo-inducible promoters and whether this would trigger anti-Vi antibodies through the use of Vi-expressing live bacteria. Our results show that Vi expression in the liver and spleen is downregulated with the progression of infection and that the Vi-negative population of bacteria becomes prevalent by day 4 postinfection. Furthermore, we showed that replacing the natural tviA promoter with the promoter of the SPI-2 gene ssaG resulted in sustained Vi expression in the tissues. Intravenous or oral infection of mice with a strain of S. Typhimurium expressing Vi under the control of the ssaG promoter triggered detectable levels of all IgG subclasses specific for Vi. Our work highlights that Vi is downregulated in vivo and provides proof of principle that it is possible to generate a live attenuated vaccine that induces Vi-specific antibodies after single oral administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.